Lacosamide Linked To Higher Fracture Risk Than Levetiracetam

What was studied

This study looked at whether fracture risk differed between two seizure medicines, lacosamide and levetiracetam, when each was used alone in adults with epilepsy. The researchers used a large health records network called TriNetX and identified adults who started one of these medicines and were not taking other antiseizure medicines at the same time.

They matched patients in the two groups so they were similar in demographics, comorbidities, and medications. After matching, there were 20,888 people in each group. The main outcome was a combined fracture outcome over 5 years that included hip, cervical vertebra, and forearm fractures.

What they found

Over 5 years, fractures occurred more often in the lacosamide group than in the levetiracetam group. The main combined fracture outcome occurred in 2.86% of people taking lacosamide and 2.09% of people taking levetiracetam. The analysis found an association with higher fracture risk in the lacosamide group (HR 1.27; 95% CI 1.11-1.44).

The lacosamide group also had higher risk of forearm fracture, major osteoporotic fracture, and incident osteoporosis. A sensitivity analysis requiring at least 6 prescription fills and excluding additional newer generation antiseizure medicines preserved the direction of effect.

Limits of the evidence

This was a retrospective study using medical records, so it can show an association but cannot prove that lacosamide caused more fractures. Even though the groups were matched carefully, residual confounding may still have affected the results.

The study only included adults and compared lacosamide with levetiracetam, not with all seizure medicines. The abstract does not give details about dose, reasons for choosing one drug over the other, or results for different age groups.

For families and caregivers

For families, this study suggests that bone health may be one factor to think about when comparing seizure medicines in adults, especially for someone with elevated skeletal fragility. It does not mean lacosamide is unsafe for everyone, and it does not show that one medicine is always the best choice.

Treatment decisions also depend on seizure type, side effects, other health problems, and how well a medicine works for the person. This study may be useful as part of a broader conversation with a clinician about seizure control and bone health.

What to watch next

Useful next studies would include research that better addresses residual confounding or prospective head-to-head comparisons.

Terms in this summary

monotherapy

Treatment with just one medicine instead of a combination of medicines.

retrospective study

A study that looks back at existing medical records rather than following people forward from the start.

propensity score matching

A method used to make two treatment groups more similar so the comparison is fairer.

hazard ratio

A measure of how often an event happens in one group compared with another over time.

osteoporosis

A condition in which bones become weaker and more likely to break.

major osteoporotic fracture

A category of fracture linked to bone fragility.

residual confounding

Hidden or unmeasured differences between groups that may affect the results.

Class III evidence

A lower level of medical evidence, usually from non-randomized or observational studies.